09:46 AM EST - Microbix Biosystems Inc. : Announces that the contract development and manufacturing organization engaged by its funding and commercialization partner, Sequel Pharma, LLC, has modernized production methods for the active ingredient of Kinlytic® urokinase, a biologic for dissolving blood clots. Microbix Biosystems Inc.
shares T.MBX are trading up $0.02 at $0.25.
